365
Participants
Start Date
March 23, 2023
Primary Completion Date
December 15, 2026
Study Completion Date
September 5, 2027
GV20-0251
Increasing doses of GV20-0251 administered by intravenous (IV) infusion once or twice every 3 weeks as monotherapy.
GV20-0251
GV20-0251 preliminary RP2D administered by IV infusion as monotherapy.
GV20-0251 and Pembrolizumab [KEYTRUDA®]
GV20-0251 administered by IV infusion at 10 mg/kg once every 3 weeks or at increasing doses up to the preliminary RP2D determined in Part A. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
GV20-0251 and Pembrolizumab [KEYTRUDA®]
GV20-0251 administered by IV infusion at preliminary RP2D from Part C. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
RECRUITING
NYU Langone Health, New York
RECRUITING
Virginia Cancer Specialists, Fairfax
NOT_YET_RECRUITING
Florida Cancer Specialists & Research Institute, LLC, Fort Myers
NOT_YET_RECRUITING
Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
RECRUITING
Community Health Network, Inc., Indianapolis
RECRUITING
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit
RECRUITING
Oncology Consultants, P.A., Houston
RECRUITING
The University of Texas M. D. Anderson Cancer Center, Houston
NOT_YET_RECRUITING
HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE, Denver
RECRUITING
The Angeles Clinic and Research Institute, Los Angeles
RECRUITING
Oregon Health & Science University, Portland
RECRUITING
Yale University, New Haven
RECRUITING
Massachusetts General Hospital, Boston
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
GV20 Therapeutics
INDUSTRY